Jefferies Boosts Numbers On Regeneron (REGN) After Strong Q4, Outlook

Jefferies raised estimates and its price target on Buy-rated Regeneron Pharma (NASDAQ: REGN) from $111 to $127 following a "spectacular" Q4 and raised guidance.

The firm comments, "Following a spectacular Q4, REGN hikes its FY12 U.S. Eylea sales guidance to $250-$300M, sig higher than our $181M and cons $159M. We believe eye infection risks are ~in-line with historicals with most reported events likely driven by poor physician practice. We increase our PT to $127 from $111 on stronger Eylea traction."

Q1 EPS goes up form ($0.56) to ($0.16), FY12 up from ($1.68) to ($0.36) and FY13 from ($0.13) to $1.79.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $114.65 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Morgan Stanley Downgrades oOh!media (OML:AU) to Equalweight
• Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer